Sativa Wellness Group Inc.
VANCOUVER, BC / ACCESSWIRE / July 23, 2021 / Sativa Wellness Group Inc. (CSE:SWEL) ("Sativa Wellness" or the "Company") is pleased to announce its new business strategy following a strong start to the year.
Highlights for first half of 2021
- Change in leadership with the founder returning as Chair and a strong top team appointed.
- The Wellness business aligned in three clear divisions as CBD products, Cannabinoid testing and Clinic Testing Services each with a clear business head.
- Q1 the best quarterly turnover to date for any quarter since Sativa Wellness and its predecessor Sativa Group Plc started in 2018 at £1.37m.
- Q2 produced even stronger revenue results with full results for the first 6 months to be reported in August.
- The business is maintaining a healthy cash position to further its acquisition strategy.
- The main trading company Goodbody Botanicals has generated profits year to date in 2021 from a loss-making position in previous years.
- The novel food submission submitted on time, full acceptance is still in progress.
- ISO 17025 achieved by the Phytovista Laboratory for cannabinoid testing.
- Roll out of 47 COVID testing clinics to build the newest division of the business.
- Successful placement to invest in the future business.
Strategic direction
The business will align the legal entities within the Group with the divisions as laid out above separating clinic testing from CBD so clearer reporting will be available in 2022. The plans we have in place and are progressing include:
CBD Products-Goodbody Brand
- Secure sales through well-known online platforms.
- Build a ‘membership' model for CBD to build predictable revenues.
- Extent product range to include drinks and vape.
- Secure distribution agreements with partners throughout Europe.
- Progress merger and acquisitions to increase the product range and revenue.
- Expand the production of an increased range in Poland.
Cannabinoid Testing
- Expanding the scope of the ISO17025 accreditation.
- Work with the Polish laboratory team to expand cannabinoid testing in Europe.
- Position the business to partner with institutions as a key supplier.
Clinic Services
- Significantly increase the footprint of clinics across the UK.
- Expand COVID 19 testing, incorporating Influenza A&B and RSV.
- Introduce a range of wellness testing through the clinic network.
- Introduce technical solutions for faster testing.
- Introduce corporate testing.
Geremy Thomas, Executive Chairman, says; "It has been six months since I felt compelled to take back leadership of Sativa and I am pleased to say the changes made have produced strong results both financially and operationally. The next phase will be exciting for us all."
Marc Howells, Chief Executive Officer, says "I am delighted to join such an exciting Company and evolve the roadmap to ensure a successful Group, where the share value truly reflects the sum of the parts: an international, accredited laboratory testing facility in Phytovista, a European CBD (gold-standard) manufacturing and retail division with a broad product range combined with digital marketing expertise, and a Covid / Wellness division increasing its footprint and testing facilities delivering our mission - Wellness as a lifestyle choice. We plan to hold our AGM in September where I look forward to updating our loyal investors with progress. In the meantime, thank you for your patience."
On behalf of the Board of Directors,
Marc Howells
Chief Executive Officer
Sativa Wellness Group Inc.
+44 (0) 20 7971 1255
enquiries@sativawellnessgroup.com
www.sativawellnessgroup.com
Anne Tew
Chief Financial Officer
Sativa Wellness Group Inc.
+44 (0) 20 7971 1255
enquiries@sativawellnessgroup.com
www.sativawellnessgroup.com
Neither the Canadian Securities Exchange nor its Market Regulator (as defined in the policies of the Canadian Securities Exchange) accept responsibility for the adequacy or accuracy of this release. This news release contains certain 'forward-looking information' within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Sativa's control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'expects' or 'does not expect', 'is expected', 'budget', 'scheduled', 'estimates', 'forecasts', 'intends', 'anticipates' or 'does not anticipate', or 'believes' 'plan is' or variations of such words and phrases or may contain statements that certain actions, events or results 'may', 'could', 'would', 'might' or 'will be taken', 'will continue', 'will occur', 'will be achieved' or 'shortly'. The forward-looking information and forward-looking statements contained herein include, but are not limited to information under the heading strategic direction relating to the three business areas of CBD products, Cannabinoid testing and clinic service and that the company will evolve the roadmap to ensure a successful Group, where the share value truly reflects the sum of the parts: an international, accredited laboratory testing facility in Phytovista, a European CBD (gold-standard) manufacturing and retail division with a broad product range combined with digital marketing expertise, and a Covid / Wellness division increasing its footprint and testing facilities.
Although Sativa believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this news release are made as of the date of this press release, and include but are not limited to information concerning the under the Strategic direction header and the likely impact on the share price on the actions being undertaken. Sativa does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
SOURCE: Sativa Wellness Group Inc.
View source version on accesswire.com:
https://www.accesswire.com/656843/Sativa-Wellness-Group-Announces-a-Strong-Position-and-Clear-Strategy
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
SK tes Launches New Circular IT Facility in Shannon, Expanding Ireland’s Role in Global Sustainable Tech Services24.4.2025 09:30:00 CEST | Press release
SHANNON, IE / ACCESS Newswire / April 24, 2025 / SK tes, a global leader in sustainable IT asset disposition (ITAD) and technology lifecycle services, has announced plans to open a new 36,000 square foot purpose-built facility in Shannon, marking a major vote of confidence in Ireland's thriving data and technology sector. The new facility will deliver comprehensive ITAD, data center decommissioning, and technology lifecycle management services to some of Ireland's largest enterprises, including hyperscale data center operators, while supporting national sustainability and circular economy goals. It will also create over 25 skilled jobs in one of the country's fastest-growing tech regions. "Ireland is at the forefront of Europe's digital economy, and our investment in Shannon reinforces our commitment to helping Irish companies manage technology securely, sustainably, and at scale," said Eric Ingebretsen, Chief Commercial Officer at SK tes. "This facility will allow us to meet the uniqu
Sauce Labs Launches Industry-First Enterprise Scale iOS 18 Testing on Sauce Labs Virtual Device Cloud, Boosting Test Speeds up to 40%24.4.2025 08:00:00 CEST | Press release
Leading test automation platform, powering development for over 300,000 active users and having executed more than 8 billion tests, enables developers and QA teams to ensure app quality on Apple's latest OS with unprecedented performance and scale. SAN FRANCISCO, CA / ACCESS Newswire / April 24, 2025 / Sauce Labs Inc., the leading platform for continuous quality, trusted by dev teams around the world to deliver apps users love, today announced the general availability of iOS 18 testing on its Virtual Device Cloud (VDC). Leveraging its new, high-performance Apple Silicon cloud infrastructure, Sauce Labs offers the market's most scalable enterprise-ready solution for automated mobile app and web testing on iOS 17.5, iOS 18, and beyond, enabling teams to execute tests up to 40% faster compared to previous versions. This launch addresses the critical need for timely testing support driven by Apple's transition to its proprietary Apple Silicon architecture and the rapid adoption rate of new
Introducing NUGEN(R) HLD-CD by Arxada: A Game-Changer in Healthcare Disinfection24.4.2025 07:00:00 CEST | Press release
Delivering Effective Germ Control in Five Minutes BASEL, CH / ACCESS Newswire / April 24, 2025 / Arxada, a global leader in specialty chemicals and innovative solutions, announces the launch of NUGEN® HLD-CD, a revolutionary healthcare disinfectant. This game-changing solution disinfects medical devices in just five minutes, ensuring that even the most resilient microorganisms, which can withstand harsh conditions, are destroyed.* NUGEN® HLD-CD is designed to meet the rigorous demands of healthcare environments. Its broad efficacy spectrum and short contact times make it suitable for all critical areas, including operating rooms, isolation areas, and intensive care units where speed and safety are essential. "We are excited to introduce NUGEN® HLD-CD to the healthcare market," said Uwe Holland, Head of Professional Hygiene EMEA at Arxada. "This solution is a game-changer in disinfection technology for healthcare facilities, providing professionals with a powerful means to improve patie
TCL Introduces the TCL T6C-UK Fire TV Series with QLED 4K, HDR PRO, and Freely23.4.2025 07:30:00 CEST | Press release
LONDON, UNITED KINGDOM / ACCESS Newswire / April 23, 2025 / TCL, the leading consumer electronics brand and the world's second-largest TV brand as well as an official sponsor of the Olympic Games, is proud to announce the launch of its highly anticipated T6C-UK TV series. The new range offers screen sizes from 43" to 85", ensuring there is a perfect option for every home. Featuring QLED technology, 4K resolution, and an intuitive Fire TV experience, the T6C-UK series offers exceptional picture quality, seamless content access, and smart functionality. The TCL T6C-UK series comes Freely-enabled, offering a seamless way to enjoy live and on-demand TV - all in one place and completely free. With Freely built-in, users can access their favourite streaming apps at the click of a button, eliminating the need to switch between platforms. From major channels to must-watch shows, everything is easily accessible from a single, intuitive home screen. Powered by Fire TV, the T6C-UK series also fea
BioNxt Solutions Prepares for Human Bioequivalence Study For MS23.4.2025 03:05:00 CEST | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment. BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish. T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom